


Ask a doctor about a prescription for TAPIMIO 50 mg PROLONGED-RELEASE TABLETS
Package Leaflet: Information for the User
Tapimio 50 mg prolonged-release tablets EFG
Tapentadol
Read this package leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the package leaflet
Tapentadol - the active substance in Tapimio - is a potent analgesic belonging to the class of opioids.
Tapimio is used for the treatment of severe chronic pain in adults that can only be adequately managed with an opioid analgesic.
Do not take Tapimio:
Warnings and precautions
Talk to your doctor or pharmacist before you start taking this medicine:
This medicine contains tapentadol, which is an opioid medicine. Repeated use of opioid analgesics can reduce their effectiveness (you can get used to them). It can also lead to dependence and abuse, which can result in a potentially fatal overdose. It is essential that you inform your doctor if you think you may have developed dependence on this medicine. Its use (even at therapeutic doses) can cause physical dependence, which may cause you to suffer from withdrawal effects and a recurrence of your problems if you stop taking this treatment suddenly.
Tapentadol can cause physical and psychological addiction. If you tend to abuse medicines or are dependent on medicines, you should only take these tablets for short periods under strict medical supervision.
Respiratory disorders related to sleep
Tapentadol can cause respiratory disorders related to sleep, such as sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, nighttime awakenings due to difficulty breathing, difficulty maintaining sleep, or excessive daytime sleepiness. If you or someone else observes these symptoms, consult your doctor. Your doctor may consider reducing the dose.
Other medicines and Tapimio
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
However, if your doctor prescribes tapentadol with sedative medicines, they will limit the dose and duration of concomitant treatment.
Taking opioids with medicines used to treat epilepsy, nerve pain, or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression, and can be potentially fatal.
Tell your doctor if you are taking gabapentin or pregabalin or any other sedative medicine and follow your doctor's dosage recommendation to the letter.
It may be helpful to inform friends or family members so they are aware of the signs and symptoms mentioned above. Contact your doctor when you experience these symptoms.
Taking Tapimio with food, drinks, and alcohol
Do not consume alcohol while taking this medicine, as some of its side effects, such as drowsiness, may increase. Food intake does not affect the effect of this medicine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Do not take this medicine:
The use of tapentadol is not recommended:
Driving and using machines
This medicine may cause drowsiness, dizziness, and blurred vision, and may affect your reactions.
This can occur especially when you start taking tapentadol, when your doctor changes your dose, or when you drink alcohol or take tranquilizers. Ask your doctor if you can drive or use machines.
Follow the instructions for administration of this medicine exactly as told by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Your doctor will adjust the dose according to the intensity of your pain and your personal sensitivity to pain. You should generally take the minimum effective dose to relieve the pain.
Adults
The recommended starting dose is 50 mg taken twice a day, approximately every 12 hours. Daily doses above 500 mg of tapentadol are not recommended.
Your doctor may prescribe a different dose or regimen, and more suitable if necessary. If you think the effect of these tablets is too strong or too weak, consult your doctor or pharmacist.
Elderly patients
In elderly patients (over 65 years of age), the dose does not usually need to be adjusted. However, the elimination of tapentadol may be delayed and slower in certain patients in this age group. If this applies to you, your doctor may prescribe a different regimen.
Liver and kidney diseases (hepatic and renal insufficiency)
Patients with severe liver problems should not take these tablets. If you have moderate liver problems, your doctor will prescribe a different regimen. In cases of mild liver problems, no dose adjustment is necessary.
Patients with severe kidney problems should not take these tablets. In cases of mild or moderate kidney problems, no dose adjustment is necessary.
Use in children and adolescents
Tapentadol is not indicated in children and adolescents under 18 years of age.
How and when to take Tapentadol
Tapentadol should be taken orally.
Always swallow the tablet with sufficient liquid. Do not chew or crush them, as this could lead to an overdose because the active substance will be released in your body too quickly.
You can take the tablets with or without food.
The tablet can be divided into equal doses.
The coating of the tablet may not be completely digested and may therefore appear, apparently unchanged, in the feces. This should not worry you, as the active substance of the tablet will have already been absorbed by the body, and what you see is only the empty coating.
Instructions for opening the blister pack
This medicine is packaged in child-resistant, perforated unit-dose blisters.
You cannot push the tablets through the blister pack. Follow these instructions for opening the blister pack:



How long to take Tapentadol
Do not take the tablets for longer than your doctor has told you.
If you take more Tapentadol than you should
After taking very high doses, you may experience some of the following effects:
If you experience any of these effects, you should immediately call a doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount used. It is recommended to take the package and package leaflet of the medicine to the healthcare professional.
If you forget to take Tapimio
If you forget to take a tablet, you will probably feel pain again. Do not take a double dose to make up for forgotten doses, but continue taking the tablets as before.
If you stop taking Tapimio
If you stop or discontinue treatment too early, you will probably feel pain again. If you want to stop treatment, consult your doctor before doing so.
Generally, patients do not experience any side effects after stopping treatment, but in rare cases, people who have taken the tablets for a long time may feel unwell if they stop taking them suddenly.
The symptoms can be:
If you experience any of these symptoms after stopping treatment, consult your doctor.
Do not stop taking this medicine abruptly, unless your doctor tells you to do so. If your doctor wants you to stop taking these tablets, they will tell you how to do it, which may involve gradually reducing the dose.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medications, this medication can produce adverse effects, although not all people suffer from them.
Adverse effects or important symptoms to be aware of and what to do if you are affected by them:
If you experience any of these important symptoms, consult your doctor immediately.
Adverse effects that may occur:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Frequency not known(frequency cannot be estimated with available data)
In general, the possibility of having suicidal thoughts and behaviors increases in patients with chronic pain. Additionally, some medications for treating depression (with an impact on the brain's neurotransmitter system) may increase this risk, especially at the start of treatment. Although tapentadol also affects neurotransmitters, experience in patients has not proven that it increases this risk.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be thrown away through drains or into the trash. Deposit the containers and medications you no longer need at the SIGRE Point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. This way, you will help protect the environment.
Composition of Tapimio
The active ingredient is tapentadol.
Each prolonged-release tablet contains tapentadol phosphate equivalent to 50 mg of tapentadol.
The other components are:
Tablet core: microcrystalline cellulose (E460); hypromellose (E464); anhydrous colloidal silica (E551); magnesium stearate.
Tablet film: hypromellose (E464); glycerol (E422); talc (E553b); microcrystalline cellulose (E460); titanium dioxide (E 171).
Appearance of the Product and Package Contents
Prolonged-release tablets, biconvex, oblong, white (6 mm x 13 mm), with a score on both sides.
The tablet can be divided into equal doses.
Tapimio 50 mg is packaged in child-resistant, single-dose precut blisters, in containers of 20, 24, 30, 50, 54, 60, or 100 prolonged-release tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Manufacturer:
Develco Pharma GmbH
Grienmatt 27
79650 Schopfheim
Germany
Neuraxpharm Arzneimittel GmgH
Elisabeth-Serbert-Strasse 23
40764 Langenfeld
Germany
This medication is authorized in the member states of the European Economic Area under the following names:
Germany Tapentadol neuraxpharm 50 mg Retardtabletten
Ireland Tapimio 50 mg prolonged-release tablets
Spain Tapimio 50 mg prolonged-release tablets EFG
Sweden Tapimio Depot 50 mg depottabletter
Date of the last revision of this prospectus: September 2022
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of TAPIMIO 50 mg PROLONGED-RELEASE TABLETS in November, 2025 is around 22.01 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TAPIMIO 50 mg PROLONGED-RELEASE TABLETS – subject to medical assessment and local rules.